The unprecedented global pandemic of COVID‐19 is currently occupying the attention of physicians worldwide. This disease caused by the novel coronavirus, now designated severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is primarily an upper respiratory tract infection. However, it does impact on all specialties as medical organisations are redirected to fight the infection. The impact of COVID‐19 on gastroenterology is multifaceted. Firstly, the effect of virus SARS‐CoV‐2 is there on the GI tract.[^1^](#ygh2401-bib-0001){ref-type="ref"} Secondly, there is the effect of the highly infectious agent on the ongoing care of GI and liver patients, particularly at endoscopy where close contact with the patient may result in potential contamination. Finally there is the effect of the redirection of healthcare priorities and the negative impact it may have on many important gastroenterology services.

SARS‐CoV‐2 is an enveloped, single‐stranded RNA virus belonging to the beta coronavirus genus. The virus enters cells via the angiotensin converting enzyme 2 (ACE2) receptor. ACE2 is highly expressed in gastrointestinal mucosal cells from the oesophagus to the colon. Early reports of post‐mortem on patients who had COVID‐19 showed virus affecting oesophageal tissue.[^2^](#ygh2401-bib-0002){ref-type="ref"} The virus could thus infect GI mucosal cells and survive and shed into the lumen. SARS‐CoV‐2 has been detected in faecal samples of 48% of patients who had diarrhoeal symptoms. Even patients without GI symptoms may shed the virus in the stool. Thus, the virus spread while patients were pre‐symptomatic or asymptomatic.[^3^](#ygh2401-bib-0003){ref-type="ref"} More worryingly, the viral shedding might last for more than a month.[^4^](#ygh2401-bib-0004){ref-type="ref"}

Unsurprisingly, many patients exhibit GI symptoms. The most common symptom is loss of appetite which is usual for pyrexial illness anyway as well as nausea and vomiting. Diarrhoea is variously reported to be present in up to 48% of hospitalised patients but the largest study now published of 7736 patients with Covid‐19 diarrhoea was found in only 3.8%.[^1^](#ygh2401-bib-0001){ref-type="ref"} It is hard to explain the differences in reporting, but we have to assume that this symptom is not common and/or transient. There appears to be similar prevalence of diarrhoea in both with mild or severe disease. There are other confounding factors in particular the use of drugs which may cause diarrhoea in these patients, particularly antibiotics and anti‐viral agents. Raised transaminases occur in 21% of infected individuals in this study and this could also be due to drugs used rather than the infection itself.[^1^](#ygh2401-bib-0001){ref-type="ref"} In another study, 29% of hospitalised patients were found to have liver injury, and 17% had evidence of pancreatic injury, as manifested by elevated pancreatic laboratory studies.[^5^](#ygh2401-bib-0005){ref-type="ref"}

The second area of concern to the gastroenterologist is its effect on endoscopic procedures. The virus appears to be shed in the faeces for up to a month even after the patient becomes symptom free. This may be the case for an unknown number of asymptomatic patients as well. Hence known patients with COVID‐19 should be considered as high risk when procedures like colonoscopy and flexible sigmoidoscopy are carried out. Thus extra precaution, personal protection equipment and scrupulous hand washing should be mandated and disinfection of surfaces in endoscopy rooms, computer mouse and keyboards and all possibly contaminated surfaces is required. This may also apply to all patients as there are an unknown number of asymptomatic patients who may shed the virus in the stool.

The third area of concern and perhaps least addressed is the effect of the diversion of healthcare resources to the fight against COVID‐19. Other services are put on hold. This includes important mortality affecting areas like cancer diagnosis and screening. Mortality from GI cancers, in common with most cancers, is greatly affected by how early a stage it is detected. There is a worryingly number of patients who have mild GI symptoms whose diagnostic procedures may be greatly delayed by the pandemic.[^6^](#ygh2401-bib-0006){ref-type="ref"} On top of all this, lack of face‐to‐face clinic consultations during the lockdown may cause patients with chronic GI diseases like inflammatory bowel diseases to suffer in silence while their management remain sub‐optimal.

Sound information, good science and responsible journal reporting must be upheld. In this issue of GastroHep we present two papers of considerable interest to general gastroenterologist. The first is a network meta‐analysis of various treatments for decompensated liver disease in the prevention of paracentesis‐induced circulatory dysfunction (PICD). They demonstrated that midodrine for 3 days is more economical and superior (or at least non‐inferior) to albumin in the prevention of PICD in cirrhosis patients undergoing large volume paracentesis.[^7^](#ygh2401-bib-0007){ref-type="ref"} In another study, Minghao Li et al investigated the possible role of bisphosphonates and risk of oesophageal cancer.[^8^](#ygh2401-bib-0008){ref-type="ref"} They found after an exhaustive meta‐analysis that bisphosphonates is not associated with the development of oesophageal cancer.
